Skip to main content
Click here to get access to our Free Course on Momentum Investing Strategy

NSE · BALPHARMA

BAL PHARMA

HealthcarePharmaceuticals & Biotechnology₹135 cr market cap
₹84.61 ▼ -1.62% today As of 19 Nov 2026
52-week low ₹60.4252-week high ₹114.45

-24.9% from the 52-week high · +42.3% above the low

Bal Pharma Ltd. is a holding company, which engages in the research, development, and commercialization of pharmaceutical products. The company is headquartered in Bangalore, Karnataka. The firm is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). The company is specialized in bulk actives, prescription drugs, generics and pharma intermediates. Its focused therapeutic areas are anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. The company offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment. Its finished formulation products cover dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments. The firm offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.

The short version. BAL PHARMA reported revenue of ₹90 crore for Sep 2026, up 21.6% from a year earlier. Net profit was ₹1 crore (up 0.0% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 50.86% in Sep 2026, up 0.00 points over 8 quarters.

1 · The price

How has the stock traded?

BAL PHARMA trades 24.9% below its 52-week high and 42.3% above its 52-week low.

Change over period: —

1M-6.2%
3M+1.4%
6M+7.7%
1Y+8.8%

2 · The business

Is it growing?

Sales, year on year+21.6%

Sep 2026 revenue of ₹90 cr.

Profit, year on year+0.0%

Sep 2026 net profit of ₹1 cr.

Net margin1.6%

0.6 pts higher than a year earlier.

3-year growth33.9% profit

Revenue compounded at 0.9% over the same 3 years.

Reported results · ₹ crore

Revenue and profit

Show the numbers

Quarterly

Sep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue9089848874668273
Net profit11421070
Net margin %1.61.34.32.01.00.38.20.7
EPS (₹)0.890.712.261.120.450.134.230.3

Annual

FY2026FY2025FY2024FY2023FY2022FY2021FY2020FY2018
Revenue312303339304281251171212
Net profit677365-130
Net margin %2.02.42.20.92.01.9-7.50.2
EPS (₹)3.954.534.681.673.783.2-9.10.27

3 · The quality

How well does it turn capital into profit?

Return on equity was 7.6% in Mar 2026; debt to equity is 1.94.

Profitability · 4 years

Returns and margins

Mar 2026Mar 2025Mar 2024Mar 2023
Return on equity %7.69.310.74.1
Return on capital %18.018.920.916.3
EBITDA margin %10.810.410.18.5
Net margin %2.02.42.20.9

Compound growth

Revenue vs profit

3 years5 years
Revenue CAGR0.9%4.5%
Profit CAGR33.9%5.8%
Debt to equity1.94
Interest cover1.4x
Current ratio1.05
P/E ratio17.0

4 · The owners

Who holds it, and are they adding?

Promoter holding50.86%

Unchanged over 8 quarters.

Foreign institutions0.28%

Up 0.14 pts over 8 quarters.

Mutual fund schemes0

+0 versus the previous month.

Shareholding pattern (%)

Quarter by quarter

Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026Sep 2026Change
Promoter50.8650.8650.8650.8650.8650.8650.8650.860.0
FII0.140.140.150.220.140.140.150.28+0.14
DII000000000
Public49.049.048.9948.9249.0149.0148.9948.87-0.13

5 · The model view

What does our factor model say?

Factor scores, model flags and screen results for BAL PHARMA are part of the Wright portfolio review.

Run your free portfolio review

Watchouts

What to review

Model flags are shown inside the portfolio review, alongside your other holdings.

Model ratingLocked
Factor betaLocked
VolatilityLocked

Quick answers

Common questions about BAL PHARMA

What is the BAL PHARMA share price?

BAL PHARMA (BALPHARMA) last closed at ₹84.61, down 1.62% on the day. Its 52-week range is ₹60.42 to ₹114.45.

What is the market cap of BAL PHARMA?

BAL PHARMA has a market capitalisation of about ₹135 crore. Its price-to-earnings ratio is 17.0.

How are BAL PHARMA's latest results?

BAL PHARMA reported revenue of ₹90 crore for Sep 2026, up 21.6% from a year earlier. Net profit was ₹1 crore (up 0.0% year on year). Return on equity was 7.6% in Mar 2026. Promoter holding was 50.86% in Sep 2026, up 0.00 points over 8 quarters.

Who owns BAL PHARMA?

As of Sep 2026, shareholding was: Promoter 50.86%, FII 0.28%, Public 48.87%.

How many mutual funds hold BAL PHARMA?

0 mutual fund schemes held BAL PHARMA in October 2026. That compares with 0 the month before.

Corporate actions

Recent dividends, bonuses and splits

  • 18 Sep 2025 · Dividend - Rs. 1.2
  • 17 Sep 2024 · Final Dividend - Rs. 1.2
  • 18 Sep 2023 · Final Dividend - Rs. 1
  • 13 Sep 2022 · Final Dividend - Rs. 1
  • 16 Sep 2021 · Final Dividend - Rs. 1
  • 17 Sep 2019 · Final Dividend - Rs. 1

Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.

Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.